MiNK Therapeutics Inc. ( INKT ) shares are down during Wednesday’s premarket session, possibly on profit-taking after the stock rallied roughly 30% on Tuesday.

On Tuesday, the company announced a strategic collaboration aimed at developing a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.

$1.1 Million Funding for MiNK Therapeutics PRAME-TCR-iNKT Asset

Under the collaboration, MiNK Therapeutics ( INKT ) will receive approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset.

This agreement also includes a share of downstream commercial revenues, reflecting the company’s strategy to leverage its iNKT platform for precise tumor targeting and improved patient outcomes.

The partnership aims to advance the program efficiently while allowing MiNK to pursue other tumor antigen targets independently.

Notably, the company previously announced a landmark case in July 2025, where a patient achieved a complete and durable remission from metastatic testicular cancer following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy.

The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later.

Donor iNKT cells were detectable up to six months post-infusion; treatment was well-tolerated with no cytokine release syndrome or graft-versus-host disease.

INKT Shares Drop 16.06% in Premarket Trading

INKT Price Action: MiNK Therapeutics ( INKT ) shares were down 16.06% at $11.34 during premarket trading on Wednesday, according to Benzinga Pro data.

Image via Shutterstock